Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Socinski

Showing results (41-50 of 279) with videos related to

Pageof 28
Sort By:
The Oncologist|September 12, 2008
Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?Thomas E Stinchcombe, Mark A Socinski
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 31, 2009
Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapyThomas E Stinchcombe, Mark A Socinski
Seminars in Oncology|December 16, 2004
Drug development in patients with advanced non-small cell lung cancer and poor performance statusThomas E Stinchcombe, Mark A Socinski
Cancer Control : Journal of the Moffitt Cancer Center|November 15, 2016
Best Practices in Treatment Selection for Patients With Advanced NSCLCMark A Socinski, Nathan A Pennell
Nature Reviews. Clinical Oncology|July 30, 2010
Targeted therapies: Biomarkers in NSCLC for selecting cetuximab therapyThomas E Stinchcombe, Mark A Socinski
The Oncologist|September 18, 2025
In ReplyFrédérique Penault-Llorca, Mark A Socinski
Reviews on Recent Clinical Trials|May 14, 2008
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trialsCarrie B Lee, Mark A Socinski
Drugs|March 6, 2007
The role of induction therapy for resectable non-small cell lung cancerThomas E Stinchcombe, Mark A Socinski
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 3, 2013
Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approachesDavid R Spigel, Mark A Socinski
Clinical Advances in Hematology & Oncology : H&O|November 29, 2012
Clinical roundtable monograph: Recent advances in taxanes for the first-line treatment of advanced non-small cell lung cancerMark A Socinski, Ramaswamy Govindan, David Spigel
Pageof 28

Showing results (41-50 of 279) with videos related to

Sort By:
Pageof 28
The Oncologist|September 12, 2008
Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?Thomas E Stinchcombe, Mark A Socinski
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 31, 2009
Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapyThomas E Stinchcombe, Mark A Socinski
Seminars in Oncology|December 16, 2004
Drug development in patients with advanced non-small cell lung cancer and poor performance statusThomas E Stinchcombe, Mark A Socinski
Cancer Control : Journal of the Moffitt Cancer Center|November 15, 2016
Best Practices in Treatment Selection for Patients With Advanced NSCLCMark A Socinski, Nathan A Pennell
Nature Reviews. Clinical Oncology|July 30, 2010
Targeted therapies: Biomarkers in NSCLC for selecting cetuximab therapyThomas E Stinchcombe, Mark A Socinski
The Oncologist|September 18, 2025
In ReplyFrédérique Penault-Llorca, Mark A Socinski
Reviews on Recent Clinical Trials|May 14, 2008
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trialsCarrie B Lee, Mark A Socinski
Drugs|March 6, 2007
The role of induction therapy for resectable non-small cell lung cancerThomas E Stinchcombe, Mark A Socinski
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 3, 2013
Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approachesDavid R Spigel, Mark A Socinski
Clinical Advances in Hematology & Oncology : H&O|November 29, 2012
Clinical roundtable monograph: Recent advances in taxanes for the first-line treatment of advanced non-small cell lung cancerMark A Socinski, Ramaswamy Govindan, David Spigel
Pageof 28